These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 623393)

  • 1. Standardization of early drug trials in allergic diseases (with reference to a trial of doxantrazole).
    Ford RM
    Ann Allergy; 1978 Jan; 40(1):25-7. PubMed ID: 623393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of doxantrazole with calcium ions in solvents of intermediate polarity. Possible effect of ionization of the drug.
    Spitzer JC
    Int Arch Allergy Appl Immunol; 1980; 61(1):75-80. PubMed ID: 6101277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical prediction of drug distribution in vivo: studies with doxantrazole in rats.
    Caldwell IC; Mahmood S; Weatherall M
    J Pharmacokinet Biopharm; 1978 Dec; 6(6):521-37. PubMed ID: 731415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?
    Lexchin J
    Can Fam Physician; 2002 Sep; 48():1487-92. PubMed ID: 12371307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
    Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
    J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
    Ibáñez Sendín MD
    Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal requirements for drug testing in children in Germany.
    Hasskarl H
    Pediatr Pharmacol (New York); 1983; 3(3-4):361-6. PubMed ID: 6677882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
    Breman JG; Alilio MS; Mills A
    Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current malaria situation in the Republic of Kazakhstan].
    Bismil'din FB; Shapieva ZhZh; Anpilova EN
    Med Parazitol (Mosk); 2001; (1):24-33. PubMed ID: 11548308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of bioavailability in man with simulated absorption data for three doxantrazole preparations.
    Jones H; Bye A
    J Pharm Pharmacol; 1979 Nov; 31(11):730-3. PubMed ID: 41901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.